CRUCELL RECEIVES EUROPEAN PATENT COVERING PER.C6 FOR VACCINE PRODUCTION

Dutch biotechnology company Crucell N.V. has been granted a patent by the European Patent Office specifically relating to the use of its proprietary PER.C6 technology for the production of vaccines.

The patent firmly protects the use of the PER.C6 technology for the production of all nonadenoviral viruses, including influenza viruses, for use in veterinary or human vaccines.

Further, the patent quite broadly covers the production of any nonadenoviral virus on E1-immortalized cell lines. This patent further strengthens Crucell's patent position in the emerging field of cell-based vaccines.